orphenadrine and amoxapine both increase sedation. Use Caution/Monitor.Īmoxapine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.Īmobarbital and orphenadrine both increase sedation. orphenadrine and amitriptyline both increase sedation. Use Caution/Monitor.Īmitriptyline and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.Īlprazolam and orphenadrine both increase sedation. Orphenadrine and alfentanil both increase sedation. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.Īclidinium and orphenadrine both decrease cholinergic effects/transmission. abobotulinumtoxinA increases effects of orphenadrine by pharmacodynamic synergism. Closely monitor for increased neuromuscular blockade. Muscle relaxants may enhance botulinum toxin effects. Orphenadrine increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Monitor closely for signs of respiratory depression and sedation. Limit dosages and durations to the minimum required. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Avoid or Use Alternate Drug.Ĭomment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.Įither increases toxicity of the other by pharmacodynamic synergism. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.Įither increases effects of the other by Other (see comment). If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Orphenadrine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Glucagon intranasal increases toxicity of orphenadrine by Other (see comment). Avoid or Use Alternate Drug.Ĭomment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. Glucagon increases toxicity of orphenadrine by Other (see comment). Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied.
Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Orphenadrine will increase the level or effect of fedratinib by Other (see comment). Monitor closely for signs of respiratory depression and sedation.Įither increases toxicity of the other by pharmacodynamic synergism. Profound sedation, respiratory depression, coma, and death may result if coadministered. Orphenadrine, calcium/magnesium/potassium/sodium oxybates.Įither increases effects of the other by pharmacodynamic synergism.
Benzhydrocodone/acetaminophen, orphenadrine.Įither increases toxicity of the other by pharmacodynamic synergism.
0 kommentar(er)
